Top Cited Articles

Acceptance Rate

13%

Time to first decision

14 days*

Impact Factor

9.139

Impact Factor rank (JCR)

7/64

Citescore

13.5

2020 total Altmetric mentions

9,718

Respiratory follow-up of patients with COVID-19 pneumonia
George, Peter M.; Barratt, Shaney L.; Condliffe, Robin. et al
10.1136/thoraxjnl-2020-215314

COVID-19: in the footsteps of Ernest Shackleton
Ing, Alvin J.; Cocks, Christine; Green, Jeffery Peter
10.1136/thoraxjnl-2020-215091

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
Shields, Adrian; Faustini, Sian E.; Perez-Toledo, Marisol. et al
10.1136/thoraxjnl-2020-215414

Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E-coli pneumonia
Park, Jeonghyun; Kim, Seonguk; Lim, Hyungsun. et al
10.1136/thoraxjnl-2018-211576

Help, hinder, hide and harm: what can we learn from the interactions between Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections?
Limoli, Dominique Hope; Hoffman, Lucas R.
10.1136/thoraxjnl-2018-212616

Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester
Crosbie, Phil A.; Balata, Haval; Evison, Matthew. et al
10.1136/thoraxjnl-2017-211377

Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination
Hanquet, Germaine; Krizova, Pavla; Valentiner-Branth, Palle. et al
10.1136/thoraxjnl-2018-211767

British Thoracic Society Guideline for bronchiectasis in adults
Hill, Adam T.; Sullivan, Anita L.; Chalmers, James D. et al
10.1136/thoraxjnl-2018-212463

Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial
Duiverman, Marieke L.; Vonk, Judith M.; Bladder, Gerrie. et al
10.1136/thoraxjnl-2019-213303

Targeted screening for lung cancer is here but who do we target and how?
Baldwin, David; O’Dowd, Emma; Ten Haaf, Kevin
10.1136/thoraxjnl-2020-215156

COVID-19: community CPAP and NIV should be stopped unless medically necessary to support life
Barker, Joseph; Oyefeso, Oluwatobiloba; Koeckerling, David; Mudalige, Nadeesha Lakmal; Pan, Daniel
10.1136/thoraxjnl-2020-214890

External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules
Baldwin, David R.; Gustafson, Jennifer; Pickup, Lyndsey. et al
10.1136/thoraxjnl-2019-214104

Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey
Flower, Barnaby; Brown, Jonathan C.; Simmons, Bryony. et al
10.1136/thoraxjnl-2020-215732

A potential role of microvesicle-containing miR-223/142 in lung inflammation
Zhang, Duo; Lee, Heedoo; Wang, Xiaoyun. et al
10.1136/thoraxjnl-2018-212994

Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis
Njock, Makon-Sebastien; Guiot, Julien; Henket, Monique A. et al
10.1136/thoraxjnl-2018-211897

Case for continuing community NIV and CPAP during the COVID-19 epidemic
Baker, Jillian G.; Sovani, Milind
10.1136/thoraxjnl-2020-214913

Return to work after critical illness: a systematic review and meta-analysis
Kamdar, Biren B.; Suri, Rajat; Suchyta, Mary R. et al
10.1136/thoraxjnl-2019-213803

Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis
Fermont, Jilles M.; Masconi, Katya L.; Jensen, Magnus T. et al
10.1136/thoraxjnl-2018-211855

Second round results from the Manchester ‘Lung Health Check’ community-based targeted lung cancer screening pilot
Crosbie, Phil A.; Balata, Haval; Evison, Matthew. et al
10.1136/thoraxjnl-2018-212547

PGC1 alpha repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state
Caporarello, Nunzia; Meridew, Jeffrey A.; Jones, Dakota L. et al
10.1136/thoraxjnl-2019-213064